Chromosomal regions of allelic imbalance in tumors are predicted to de®ne the general location of tumor suppressor genes. We previously localized a putative breast tumor suppressor gene to a 3 cM region on 17q25 by deletion mapping of microsatellite markers in breast tumors. To determine if the same 17q25 region of loss is important in the genesis of other tumor types, 32 ovarian tumors and 24 prostate tumors, as well as 33 additional breast tumors, were analysed with 17q25 polymorphic microsatellite markers. While no signi®cant loss was observed in prostate tumors, greater than half of ovarian tumors exhibited loss coincident with the candidate region previously de®ned in breast tumors. These results suggest that one or more novel tumor suppressor genes exist on 17q25 within a concordant region of interstitial loss de®ned in both breast and ovarian neoplasms.
Loss of heterozygosity (LOH) in neoplastic tissues is proposed to de®ne one of two mutational events necessary to inactivate both alleles of a recessive tumor suppressor gene and thus acts as a molecular guidepost for the location of such a gene (Hansen and Cavenee, 1987) . Further characterization of these growth regulatory genes often reveals mutations in tumors derived from a wide spectrum of tissues, suggesting that the genes may play a signi®cant role in human carcinogenesis (Skuse and Ludlow, 1995) . Chromosome 17 is one of the most frequently lost chromosomes in human malignancies (Seizinger et al., 1991) . Observations of multiple LOH regions along the short and long arms of chromosome 17 in breast and ovarian tumors (Jacobs et al., 1993; Godwin et al., 1994; Kirchweger et al., 1994; Schultz et al., 1996) imply the location of multiple as yet unidenti®ed suppressor genes involved in the genesis of these neoplasms. Previously, we examined 39 matched normal and breast tumor tissues and re®ned the location of a putative tumor suppressor gene on 17q25 to a 3 cM region¯anked by D17S722 and D17S802 that showed allelic imbalance in 54% of tumors (Kalikin et al., 1996) . As an increased risk of ovarian cancer is seen in individuals with breast cancer, often due to BRCA1 mutations (Szabo and King, 1995) , and as an increased risk of prostate cancer is reported in men with family histories of breast cancer, often due to mutations in BRCA1 or BRCA2 (Arason et al., 1993; Szabo and King, 1995; Thorlacius et al., 1996) , we analysed ovarian and prostate tumors for LOH with 17q25 microsatellite markers near and within our candidate breast tumor suppressor region to determine if this same region could be important in the pathogenesis of these tumor types.
A panel of ovarian tumors and prostate tumors with matching normal tissues was analysed for LOH by PCR ampli®cation using 17q25 short tandem repeat polymorphic markers (STRPs) D17S2058, D17S722, D17S937 and D17S802 (Table 1) . Of 32 ovarian tumors studied, at least one marker was lost in 19/32 tumors (59%), with the highest percentage of loss (56%) observed at D17S722 (15 of 27 informative tumors) and D17S937 (14 of 25 informative tumors). Tumor 69 was hemizygous at a single 17q25 locus, D17S722, with retention of the¯anking 17q25 loci D17S2058 and D17S937, and tumor 38 showed loss at a single 17q25 locus D17S937 with retention of thē anking 17q25 markers D17S722 and D17S802 ( Figure  1 ). Tumor 39 also showed loss of D17S937 with retention of¯anking 17q25 markers, although allelic imbalance was also detected in this tumor at the next more proximal 17q25 marker D17S2058. Where clear histopathological staging was available, of those ovarian tumors with 17q25 loss, 14 of 16 tumors (87%) were of stage three or four while, of those tumors with 17q25 retention, seven of 10 tumors (70%) were of stage one or two with no stage four present. Of 24 matched normal and prostate tumor samples ampli®ed, the heterozygosity frequency for each locus was comparable to the frequency observed in all three tumor types studied. However, no 17q25 loss was observed at D17S722, D17S937 and D17S802, and a single tumor was hemizygous for D17S2058. Figure 2 compares the percentage of LOH observed at each locus for the 32 ovarian, 24 prostate and 72 breast tumors. The breast tumor data are a summary of the 39 paired normal and breast tumor samples originally studied (Kalikin et al., 1996) and an additional set of 33 matched normal and breast tumor tissues that have since been analysed for LOH at 17q25. Results on the second set of 33 breast tumors also delineated the same interstitial region of 17q25 loss distal to D17S2058. Given this, the data from the second set of 33 breast tumors were combined with data from the original 39 tumors to increase the sample size.
BRCA1 at 17q21 has been shown to be altered in ovarian tumors (Futreal et al., 1994; Merajver et al., 1995a) , and multiple distinct regions of 17q LOH, including 17q22-q24, have been reported in ovarian tumors, suggesting the location of additional 17q candidate suppressor genes (Jacobs et al., 1993; Godwin et al., 1994; Wertheim et al., 1996) . To investigate the status of more proximal 17q cancer genes in relation to 17q25 loss, paired normal and ovarian tumor tissues were analysed with STRPs from BRCA1 and 17b-hydroxysteroid dehydrogenase (EDH17B) on 17q21, and from growth hormone (GH) on 17q23-24 (Table 1; Figure 1a ). Of 19 ovarian tumors with loss of at least one marker on 17q25, nine tumors (47%) showed allelic imbalance at 17q21 or 17q23-24 while seven tumors (37%) retained heterozygosity at these more proximal loci. In 13 tumors where allelic imbalance was not observed at any of the four 17q25 STRPs, proximal 17q hemizygosity was detected in only one tumor, at both 17q21 and 17q23-24. Of tumors 38 and 69, each that showed loss of a single 17q25 locus and retention of both¯anking markers, tumor 38 retained BRCA1. Tumor 69 was noninformative for BRCA1 STRPs, although EDH17B, which maps proximal to BRCA1, displayed allelic imbalance. Both tumors retained GH.
Our results in ovarian tumors de®ned a distinct region of interstitial loss on 17q25 with the greatest loss detected at the adjacent loci D17S722 and D17S937 (56%). A statistically signi®cant number of ovarian tumors with 17q25 loss were late stage tumors while those without 17q25 loss were early stage tumors (w 2 =11.71; P=0.001) suggesting that 17q25 loss occurs later in tumor progression, although additional tumors will need to be studied to con®rm this. While it is possible that this loss re¯ects random late stage instability, the fact that interstitial loss was observed in several tumors only at 17q25 without additional 17q21 or 17q23-24 loss implies that 17q25 harbors a gene critically important in the progression of ovarian carcinomas. As tumor 38 showed loss at only D17S937 and tumor 69 showed loss at only D17S722, these tumors de®ned a minimal overlapping region for the location of this novel suppressor gene. While tumor 38 appeared to contain the more proximal regions of chromosome 17 as interpreted by retention of heterozygosity at GH, BRCA1 and EDH17B, tumor 69 showed additional LOH at EDH17B. Tumor 69 may represent genomic instability secondary to the loss of BRCA1, as mutations in BRCA1 have been found in a subset of ovarian tumors (Futreal et al., 1994; Merajver et al., 1995a) . Alternatively, loss in this tumor and tumor 39, which was hemizygous for D17S2058 in addition to loss at D17S937 with retention of¯anking loci, may represent random instability or may de®ne novel suppressor genes, as discussed in more detail below. More ®ne mapping of these and additional ovarian tumors with intervening STRPs will need to be performed to elucidate these results.
In this study, the analysis of an additional 33 breast tumors con®rmed and substantiated our original data that localized a candidate tumor suppressor gene to a 3 cM region¯anked by D17S722 and D17S802 (Kalikin et al., 1996) . Furthermore, these regions of allelic imbalance that we have independently de®ned in breast and ovarian tumors directly overlap and we designate this the BROV region. One possibility is that the deletion mapping in ovarian tumors has localized the identical suppressor gene hypothesized near D17S937 in breast tumors, which suggests that the gene's location is more intermediate between D17S722 and D17S937 (based on the minimal overlapping candidate regions de®ned by tumors 38 and 69). The region around D17S722 may also harbor additional 17q25 suppressor genes (as de®ned by tumors 39 and 69) distinct from one near D17S937 (as de®ned by tumor 38). Similarly, in our initial study of breast tumors which analysed eight loci to localize a 17q25 region of interstitial loss near D17S937, three tumors were noted that showed outlying loss at a single 17q25 locus other than D17S937, leading to speculation of additional suppressor genes on 17q25 (Kalikin et al., 1996) . Identi®cation of multiple tumor suppressor genes within coincident regions of allelic loss is not unprecedented and includes DPC4/DCC (Hahn et al., 1996) and p15/p16 (Hannon and Beach, 1994). As our present analysis examined only four 17q25 loci, more detailed mapping of ovarian tumors 39, 69 and others (Fasman et al., 1996). b Unless indicated, minimal cycling conditions were used to achieve reliable ampli®ed products, generally 32 ± 36 cycles. To decrease stuttering of dinucleotide repeats, stepwise reductions in annealing temperature were necessary for D17S937 and D17S802. Denaturing temperatues were 948C except for D17S802 for which the ®nal ten cycles were denatured at 908C and annealed at 598C. PCR reactions with 17q25 STRPs contained one primer end-labeled with [g-32 P]ATP. Radioactive ampli®cation products were electrophoresed on a denaturing polyacrylamide gel. Autoradiographic ®lms were interpreted independently by two investigators, and results were con®rmed if necessary by densitometry on a Digital Imaging System (Alpha Innotech Corporation) as previously described (Kalikin et al., 1996) . Nonisotopic PCR reactions with 17q21 and 17q23-24 STRPs were electrophoresed on 1.5% standard agarose/1.5% Nusieve agarose (FMC BioProducts) gels and interpreted independently by two investigators with additional 17q25 loci is necessary to ascertain the location and number of additional suppressor genes, if any, outside the BROV region. In addition, these results greatly narrow previously localized candidate ovarian tumor suppressor regions spanning 17q23-25 (Eccles et al., 1992; Godwin et al., 1994) to an area on 17q25 which could be as small as a 3 cM region anked by D17S722 and D17S802, based on loss delimited in tumor 38 ( Figure 1 ). As we have mapped D17S785 and D17S722 to the same YAC (Kalikin et al., 1996) and thymidine kinase (TK1) coincident with a D17S802 positive YAC (less than 300 kb; data not shown), the minimal deleted region bounded by D17S722 and D17S802 is roughly equivalent to the distance spanned between D17S785 and TK1. Conversion of cRAY 6000 distances between D17S785 and TK1 on a high-resolution 17q22-q25.3 radiation hybrid map (Foster et al., 1996) indicates that the overlapping BROV region could span a physical distance of as little as 3 Mb (Figure 1a) .
As only a single prostate tumor showed loss at one of the four loci despite heterozygosity frequencies comparable to overall frequencies calculated from all three tumor types, this region of 17q25 is probably not involved in the pathogenesis of prostate cancer. In addition, LOH was detected at 13q (Cooney et al., 1996a) and 6q (Cooney et al., 1996b) in over 50% of these prostate tumor samples, substantiating the accuracy with which normal and tumor tissues were microdissected. Lack of prostate tumor involvement suggests that 17q25 loss does not simply re¯ect random chromosomal 17q25 instability associated with the generalized progression of solid tumor carcinogenesis. Future analysis on other tumor types will help substantiate our hypothesis that this BROV region harbors one or more speci®c breast and ovarian cancer genes.
In summary, these data established that a region of allelic loss on 17q25 de®ned in ovarian tumors was coincident with a previously described candidate breast tumor suppressor gene region near D17S937 (Kalikin et al., 1996) . Loss in this region did not appear to be a consequence of BRCA1 alterations as BRCA1 was retained in ovarian tumors despite loss at 17q25. It is unclear whether there are multiple distinct tissue speci®c genes or whether this BROV region of 17q25 harbors a single cancer gene that contributes to the Methods. Mammary, ovarian, and prostate adenocarcinomas, and normal tissues were obtained from The University of Michigan Department of Pathology. Hematoxylin and eosin stained slides were examined microscopically by a pathologist to delimit normal and neoplastic regions and were used as templates to outline areas on unstained slides. Cells were meticulously microdissected from slides with the tip of a single edged razor using extreme care to remain with the lines of demarcation to enrich for greater than 90% tumor nuclei in each sample. DNA was extracted by Proteinase K digestion from paran-embedded breast and ovarian tissue Kalikin et al., 1996) and from nonparan-embedded cryostat-sectioned prostate tissue (Cooney et al., 1996a) as described Figure 2 Comparison of LOH frequencies at 17q25 in ovarian, breast, and prostate tumors illustrates a common region of loss between ovarian and breast tumors. Numbers above bars indicate percentage loss at each locus calculated from informative sample pairs for each tumor type genesis of both tumor types, similar to BRCA1-linked hereditary breast cancer families who have an increased susceptibility to ovarian cancer and for which BRCA1 mutations have been found in both tumor types (Futreal et al., 1994; Merajver et al., 1995a) .
